Viatris Q3 results in line, raises FY guidance; acquires Aculys Pharma; NDA for estrogen patch

Viatris Inc

2025-Q3 EPS reported -$2.70 revenue$10,596,300,000

Total revenues for Q3 2025 in line with expectations; raising and narrowing 2025 guidance for revenues, adjusted EBITDA, adjusted EPS.
Submitted NDA for low-dose estrogen weekly patch; advancing pipeline.
Acquired Aculys Pharma, gaining rights to Pitolisant (Japan) and Spydia (Japan & Asia-Pacific).
Year-to-date capital return >$920M, including $500M in share repurchases.
CEO cites strong execution and strategic review for sustainable growth in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.